Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world oral corticosteroid burden before and after anti-IL-5 therapy in severe eosinophilic asthma
NL-OMON28832Recruiting
- Sponsor
- Medisch Centrum Leeuwarden
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of mepolizumab, reslizumab and benralizumab, sponsored by Medisch Centrum Leeuwarden. Started Oct 2020; status: recruiting.
02
Drugs
mepolizumabreslizumabbenralizumab
Beyond the preview
Go deeper on NL-OMON28832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28832.